EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity

Susan X N Lin, Philip K Ahring iD, Angelo Keramidas iD, Vivian W Y Liao, Rikke S Møller, Mary Chebib, Nathan L Absalom

Brain · 2024

DOI: 10.1093/brain/awad285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Susan X N Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia. Hauptthemen laut MEDLINE: Epilepsy, Epilepsy, Generalized, Movement Disorders. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council, Australian Research Training Program Stipend scholarship, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic variants associated with developmental and epileptic encephalopathies have been identified in the GABRB3 gene that encodes the β3 subunit of GABAA receptors. Typically, variants alter receptor sensitivity to GABA resulting in either gain- or loss-of-function, which correlates with patient phenotypes. However, it is unclear how another important receptor property, desensitization, contributes to the greater clinical severity of gain-of-function variants. Desensitization properties of 20 gain-of-function GABRB3 variant receptors were evaluated using two-electrode voltage-clamp electrophysiology. The parameters measured included current decay rates and steady-state currents. Selected variants with increased or reduced desensitization were also evaluated using whole-cell electrophysiology in transfected mammalian cell lines. Of the 20 gain-of-function variants assessed, 13 were found to alter receptor desensitization properties. Seven variants reduced desensitization at equilibrium, which acts to worsen gain-of-function traits. Six variants accelerated current decay kinetics, which limits gain-of-function traits. All affected patients displayed severe clinical phenotypes with intellectual disability and difficult-to-treat epilepsy. Nevertheless, variants that reduced desensitization at equilibrium were associated with more severe clinical outcomes. This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality. Variants that accelerated current decay kinetics were associated with slightly milder phenotypes with later seizure onset (median 4 months), unclassifiable developmental and epileptic encephalopathies or Lennox–Gastaut syndrome and no movement disorders. Our study reveals that gain-of-function GABRB3 variants can increase or decrease receptor desensitization properties and that there is a correlation with the degree of disease severity. Variants that reduced the desensitization at equilibrium were clustered in the transmembrane regions that constitute the channel pore and correlated with greater disease severity, while variants that accelerated current decay were clustered in the coupling loops responsible for receptor activation and correlated with lesser severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyEpilepsy, GeneralizedMovement DisordersAnimalsHumansInfant, NewbornGain of Function MutationMutationSeizuresMammalsReceptors, GABA-A

Stichwörter der Autor:innen

SLC12A5EIMFSGABAA receptordevelopmental and epileptic encephalopathyelectrophysiologymovement disorder

Substanzen

GABRB3 protein, humanReceptors, GABA-A

Autor:innen und Institutionen

  • Brain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • Institute for Molecular Bioscience, The University of Queensland, Saint Lucia, QLD 4072, Australia.
  • Department of Epilepsy Genetics and Personalized Medicine, Member of ERN, EpiCare, Danish Epilepsy Centre, Dianalund DK-4293, Denmark.
  • Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense DK-5230, Denmark.
  • School of Science, University of Western Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Philip K Ahring, Angelo Keramidas

Förderung

  • Australian National Health and Medical Research Council
  • Australian Research Training Program Stipend scholarship
  • Novo Nordisk Foundation
  • The Lundbeck Foundation

Zitieren

APA

Lin, S. X. N., Ahring, P. K., Keramidas, A., Liao, V. W. Y., Møller, R. S., Chebib, M., & Absalom, N. L. (2024). Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity. Brain. https://doi.org/10.1093/brain/awad285

Vancouver

Lin SXN, Ahring PK, Keramidas A, Liao VWY, Møller RS, Chebib M, et al. Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity. Brain. 2024. doi:10.1093/brain/awad285

BibTeX
@article{Lin2024,
  author = {Lin, Susan X N and Ahring, Philip K and Keramidas, Angelo and Liao, Vivian W Y and Møller, Rikke S and Chebib, Mary and Absalom, Nathan L},
  title = {Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awad285}
}
Kostenlos starten →